Ask Warren

HLB Therapeutics

115450 · KOSDAQ · ₩115450 · HLB테라퓨틱스

₩2,495▼ ₩65 (2.54%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩13B₩13B₩23B₩16B₩16B₩15B₩16B₩14B
Cost of sales₩14B₩14B₩16B₩17B₩14B₩13B₩12B₩11B
Gross profit−₩1.3B−₩694M₩7B−₩828M₩1.9B₩2.1B₩4.2B₩2.6B
Operating income−₩4.7B−₩3.2B₩4.1B−₩5.4B−₩666M−₩1.6B₩16M−₩1.8B
Net income−₩9B−₩4.4B−₩4.1B−₩5.5B₩4.5B−₩4.5B−₩21B₩20B
Net income to shareholders−₩8.9B−₩4.3B₩643M−₩5.5B₩67M−₩4.5B₩1.9B−₩2.6B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩221B₩229B₩229B₩227B₩211B₩224B₩220B₩204B
Current assets₩38B₩46B₩75B₩54B₩43B₩49B₩54B₩60B
Cash and equivalents₩11B₩17B₩20B₩24B₩6.2B₩8.1B₩18B₩8.7B
Total liabilities₩52B₩53B₩55B₩58B₩38B₩46B₩38B₩36B
Current liabilities₩49B₩35B₩26B₩46B₩33B₩36B₩32B₩18B
Borrowings₩36B₩36B₩36B₩20B₩26B₩29B₩23B₩17B
Total equity₩169B₩176B₩174B₩170B₩173B₩178B₩182B₩169B
Shareholders' equity₩144B₩151B₩150B₩146B₩151B₩154B₩157B₩147B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩3.1B−₩2.7B₩1.1B₩821M−₩5.9B−₩4.2B₩15B−₩6.8B
Capital spending₩451M₩80M₩26M₩285M₩797M₩176M₩35M₩442M
Free cash flow−₩3.6B−₩2.7B₩1.1B₩536M−₩6.7B−₩4.4B₩15B−₩7.2B

Consolidated where available. Amounts in won.

Also known as: HLB Therapeutics / HLB테라퓨틱스 / 115450 / KRX:115450

Source: KRX statistical information